<DOC>
	<DOCNO>NCT02411643</DOCNO>
	<brief_summary>This study look topical treatment synthetic Vitamin D3 , calcipotriene ointment , use standard care , work patient morphea . Skin biopsies morphea lesion treatment topical calcipotriene 0.005 % ointment analyze change RNA protein . A skin biopsy unaffected skin also obtain use control . This initial study look molecular effect topical calcipotriene human morphea-involved skin . This study look difference affect unaffected skin . This study also look clinical outcome morphea patient determine clinical predictor improvement medication .</brief_summary>
	<brief_title>Molecular Effects Topical Calcipotriene Morphea</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subjects clinicallydiagnosed biopsy proven plaquetype , guttate , linear , segmental , generalized morphea receive calcipotriene 0.005 % ointment part standard care treatment include . Subjects allow previously therapy long systemic treatment , topical therapy phototherapy 4 week prior baseline . Age â‰¥ 18 year . Ability understand willingness sign write informed consent . Subjects diagnosis morphea profundus , eosinophilic fasciitis , atrophoderma exclude . Subjects receive oral topical immunosuppression therapy phototherapy within 4 week prior enter study . Subjects may receive investigational agent . Subjects must pregnant nursing . Patients allergic lidocaine epinephrine history impair wound heal reason unable undergo skin biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>